Modigraf (Tacrolimus)

Tacrolimus, the active ingredient in Modigraf, is a calcineurin inhibitor presented as an oral formulation for oral use. It helps prevent organ transplant rejection in adult patients. GNH USA supplies Modigraf as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Tacrolimus is a calcineurin inhibitor used primarily in transplant medicine to suppress immune‑mediated graft rejection. - Organ transplant rejection: helps prevent rejection of transplanted organs by suppressing T‑cell activation and cytokine production.

Tacrolimus may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate discomfort. - Tremor: fine shaking of hands or limbs. - Nausea: occasional upset stomach. - Diarrhea: loose stools. - Hypertension: elevated blood pressure. - Hyperglycemia: increased blood sugar levels.

Serious or Rare Side Effects: - Nephrotoxicity: impaired kidney function. - Neurotoxicity: seizures or severe confusion. - Infections: opportunistic bacterial, viral or fungal infections. - Malignancy: increased risk of certain cancers. - Severe allergic reaction: rash, swelling, or anaphylaxis.

When prescribing tacrolimus, clinicians should observe several safety measures. - Therapeutic drug monitoring: maintain blood concentrations within target range. - Renal function: assess serum creatinine and glomerular filtration rate regularly. - Hepatic function: monitor liver enzymes for potential toxicity. - Pregnancy: avoid use in pregnant women unless benefits outweigh risks (Category C). - Live vaccines: contraindicated while on therapy. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and direct sunlight.

Tacrolimus interacts with several drug classes that can alter its plasma levels.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may cause toxic accumulation. - Azole antifungals (e.g., fluconazole): increase tacrolimus exposure. - Macrolide antibiotics (e.g., erythromycin): raise blood concentrations. - Grapefruit juice: potent CYP3A4 inhibition leading to higher levels. - Certain antivirals (e.g., ritonavir): markedly elevate tacrolimus.

Moderate Interactions (Monitor Closely): - Calcium channel blockers (e.g., diltiazem): may modestly increase levels. - Diuretics (e.g., furosemide): can affect renal clearance. - NSAIDs (e.g., ibuprofen): increase risk of nephrotoxicity. - Rifampin: strong inducer that reduces tacrolimus exposure. - St. John’s wort: herbal inducer that may lower drug levels.